INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death and accounts for more than a million deaths per year worldwide. 1 The disease is usually diagnosed at later stages, when curative treatment is not available. 2 The benefit from platinum-based doublet chemotherapy is modest. 3 Lung cancers are biologically and molecularly diverse 4 and have various responses to both traditional chemotherapy and targeted therapy designed to address molecular alterations that drive cancer progression. 5 The rapid evolution of genomic profiling has dramatically accelerated our knowledge of the diversity of Author affiliations appear at the end of this article.
lung cancer 4 and has generated the impetus for using genotyping as a guide for clinical care of patients with lung cancer and for creating novel design paradigms in genomics-driven clinical trials.
In the phase II Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program of personalized medicine (ClinicalTrials.gov numbers NCT00409968, NCT00411671, NCT00411632, NCT00410059, and NCT00410189) previously reported 6, 7 by our group, we prospectively biopsied tumors and, on the basis of tumor markers, we used adaptive randomization to assign patients with NSCLC to the treatment with the greatest potential benefit on the basis of cumulative data. The trial established the feasibility of performing core biopsies in pretreated patients with advanced disease and of using real-time biomarker analysis for treatment assignments, 8 and it represented a major step toward personalizing therapy for patients with NSCLC.
On this basis, the BATTLE-2 trial (BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer) capitalized on activity observed with sorafenib, 9 -11 on enhanced understanding of lung cancer biology, and on the availability of several promising agents, including MK-2206, an allosteric AKT inhibitor, 12 and AZD6244, an MEK inhibitor. 13 We could thus test novel hypotheses derived from a KRAS-mutant lung cancer mouse model in which combined MEK and PI3K/mammalian target of rapamycin inhibition resulted in synergistic tumor regression 14 and also test preclinical information that justified combining erlotinib and MK-2206 15, 16 as a means of overcoming resistance to EGFR inhibitors conferred by continued PI3K pathway activation and hepatocyte growth factor. The goals of the trial were to evaluate efficacy and identify predictive biomarkers for targeted therapies in the first stage, aiming at optimized patient selection for these therapies in the second stage. BATTLE-2 was designed with a particular emphasis on targeting mutant Kirsten rat sarcoma viral oncogene homolog (KRAS mut+) NSCLC refractory to platinum-based regimens. Here we report the results of the first stage of the BATTLE-2 trial.
PATIENTS AND METHODS

Patient Population
Patients with pretreated NSCLC at the University of Texas MD Anderson Cancer Center and Yale Cancer Center who agreed to a baseline tumor biopsy, who had Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2, and who had multiple prior lines of therapy and stable or treated brain metastases were enrolled (details for eligibility are provided in the Data Supplement). Patients were excluded if their tumor harbored EGFR sensitizing mutations or ALK gene fusions, and they were erlotinib or crizotinib naïve. All participants provided written informed consent. The MD Anderson Cancer Center and Yale Cancer Center Institutional Review Boards approved the study. The trial was monitored by an independent data and safety monitoring board.
Study Design
BATTLE-2 was a randomized, phase II, multicenter, open-label study in patients with advanced NSCLC refractory to prior platinum-based chemotherapy (Fig 1) . After molecular tumor biomarker assessments, patients were adaptively randomly assigned to four arms: arm 1, erlotinib 150 mg once per day (OSI Pharmaceuticals, Farmingdale, NY; Genentech, San Francisco, CA); arm 2, erlotinib 150 mg once per day and the AKT inhibitor MK-2206 135 mg once per week (Merck, Kenilworth, NJ); arm 3, MEK inhibitor AZD6244 100 mg per day (AstraZeneca, Wilmington, DE) and AKT inhibitor MK-2206 100 mg once per week; and arm 4, sorafenib 400 mg orally twice per day (Bayer, Whippany, NJ). Patients who received prior erlotinib were randomly assigned to one of arms 2, 3, or 4. Tumor evaluation studies were performed after two cycles (one cycle is 28 days) and every two cycles thereafter. KRAS mutation status was a stratification factor. All patients who received at least one cycle of treatment (4 weeks) were considered evaluable for response assessment, and all patients who were randomly assigned were evaluable for safety and survival analyses.
Biopsy, Molecular Analysis, and Biomarker Profiling
Patients had a mandatory baseline tumor tissue biopsy for biomarker analysis. Written informed consent was obtained from patients before the biopsy, which was performed under computed tomographic or sonographic guidance as previously described, 6, 8 including management of pneumothorax after the biopsy. Four to five fresh core needle biopsy tumor specimens approximately 1.5 cm long were collected, two of which were formalin-fixed immediately, paraffin embedded, and reviewed for presence, quantity, quality, and histologic type of tumor tissue by the dedicated pathologist. EGFR and KRAS Sanger sequencing (Data Supplement) and ALK fluorescence in situ hybridization testing 17 were performed in Clinical Laboratory Improvement Amendments-certified laboratories within 2 weeks. The remaining three core needle biopsies were frozen, stored, and allocated for gene expression analysis by messenger RNA GeneChip Human Gene 1.0 ST Array from Affymetrix (Santa Clara, CA), which tested prospectively predefined signatures, including the epithelial mesenchymal transition (EMT) signature, and DNA-targeted next-generation sequencing (NGS; Foundation Medicine, Cambridge, MA) analysis 18 in 140 tumors with sufficient material. Detailed methods are included in the Data Supplement.
Statistical Analysis
The accrual goal of stage 1 of the BATTLE-2 trial was 200 randomly assigned patients, which would allow at least 80% power with a 10% type I error rate to identify effective treatments for arms 2, 3, and 4 compared with arm 1. The overall power is 97.8% with a 20% family-wise type I error, which was chosen to prevent missing any potentially effective treatments; there was a plan to confirm the results in stage 2 and in future studies. 19 The primary end point was the 8-week disease control rate (DCR; complete or partial response or stable disease via Response Evaluation 
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Criteria in Solid Tumors [RECIST]), 20 a previously validated end point. 6, 21 A Bayesian logistic regression model was applied to model the 8-week disease control status. Under the null hypothesis, we assumed that the 8-week DCRs were 0.3 for KRAS-wild-type (wt) and 0.1 for KRAS-mutant patients. Under the alternative hypothesis, and presuming one predictive marker per arm, we assumed that the 8-week DCR increased to 80% in the predictive marker-positive patients and remained at 30% in the predictive marker-negative patients. Equal randomization was performed in the first 70 patients. Subsequently, outcome adaptive randomization was used to incorporate the 8-week disease control status, KRAS mutation, and treatment into the calculation of the posterior probability of efficacy for treatments to allow more patients to be assigned to effective therapies and fewer patients to be assigned to less effective therapies. The posterior probability was continuously updated as the data became available. This learn-as-we-go approach leveraged accumulating data to improve outcome and is described in more detail elsewhere. 19 Other end points included response rate, progression-free survival (PFS), overall survival (OS), and toxicity. Planned exploratory objectives were each treatment's efficacy in relation to biomarker profiles. PFS and OS were assessed from the date of drug start to the earliest sign of disease progression (PFS) or death as a result of any cause (PFS and OS). Tumor response was assessed every 8 weeks until disease progression. Toxicity was assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Standard statistical methods included Fisher's exact test for contingency tables and Kaplan-Meier plots and log-rank test for univariable survival data. We used a logistic regression model in a multivariable analysis to assess the relationship of DCR with clinical factors and a Cox regression to model PFS and OS and interactions between KRAS mutation and erlotinib-containing therapy. SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.2.2 (Foundation for Statistical Computing, Vienna, Austria) were used.
RESULTS
Patient Characteristics
A total of 334 patients provided consent, 60 were never biopsied because they did not fulfill eligibility criteria (n = 49) or had declining overall condition (n = 4) or decided to pursue alternative therapy (n = 7). Of 274 patients biopsied, 66 were not randomly assigned because they no longer fulfilled eligibility criteria (n = 34), they experienced a decline in overall condition (n = 17), they had a tumor that harbored a sensitizing EGFR mutation or an ALK gene fusion (n = 9), or they withdrew consent (n = 6). Randomly assigned and treated patients per treatment arm were 22 (erlotinib), 42 (erlotinib and MK-2206), 75 (MK-2206 plus AZD6244), and 61 (sorafenib; Fig 2) . Eight randomly assigned patients never received therapy because they withdrew consent (n = 5), had declining condition (n = 2), or had other reasons (n = 1). Table 1 lists the distribution of the following patient characteristics: median age, 61 years (range, 26 to 82 years); female sex, 53%; ECOG PS of 0 to 1, 85%; never smoker, 22%; former smoker, 63%; current smoker, 16%; adenocarcinoma, 73.5%; and squamous cell carcinoma, 17.5%. KRAS mutations were present in 54 patients (27%); 75 patients (38%) had prior EGFR tyrosine kinase inhibitor treatment and a median of three prior therapies, with more patients heavily pretreated in arms 2, 3, and 4 (P = .03).
Efficacy
The overall 8-week DCR in 186 patients eligible for this analysis was 48% (Table 2) , median PFS was 2.0 months (95% CI, 1.9 to 2.8 months), median OS was 6.5 months (95% CI, 5.1 to 7.6 months), and 1-year survival was 28%. Median follow-up was 20 months for PFS and 21 months for OS. There were no complete responses and only six partial responses in these heavily pretreated patients, three in arm 3 and three in arm 4. The overall 8-week DCRs were 32% (arm 1), 50% (arm 2), 53% (arm 3), and 46% (arm 4; pairwise Fisher's exact test compared with arm 1 P = .26, .12, and .30, respectively; Table 2 ).
Only PS was associated with improved DCR; the 8-week DCR for PS 0 was 77% versus only 47% for PS 1 and 36% for PS 2 Patients randomly assigned but did not receive treatments (Fisher's exact test P = .03; Data Supplement), a significant association even after adjusting for other parameters in a logistic model (Data Supplement).
PFS was almost identical among all four arms (1.8, 2.5, 2.2, and 2.1 months for arms 1, 2, 3, and 4, respectively; Fig 3A) . OS was not significantly different among the four arms (median, 7.6, 8.2, Abbreviations: DCR, disease control rate; PD, progressive disease; PR, partial response; SD, stable disease *Two patients were not evaluable because they did not complete treatment, one because the patient was retrospectively found to be noneligible because the tumor harbored an EGFR-sensitizing mutation that was not detected during screening.
www.jco.org 6.4, and 5.5 months for arms 1, 2, 3, and 4, respectively; log-rank test P = .46; Fig 3B) . In a multivariable Cox model, none of the parameters were significantly associated with PFS, and the only parameter associated with OS was PS (Data Supplement).
Biomarkers and Outcomes
Of the 54 KRAS mut+ patients, 52 were evaluable for the prespecified 8-week DCR assessment. There was no significant association between 8-week DCR and KRAS mutation status (Data Supplement).
PFS and OS were not different for patients with KRAS mut+ versus KRAS wt tumors for the whole study (Data Supplement) In KRAS wt patients, there was no difference in PFS between therapy containing erlotinib or not containing erlotinib (hazard ratio [HR] for erlotinib-containing treatments v not containing erlotinib, 0.76; 95% CI, 0.54 to 1.09; P = .13; Fig 3C) . Patients with KRAS mut+ tumors experienced a statistically significantly longer PFS if treated with therapy that did not contain erlotinib (HR, 1.95; 95% CI, 1.00 to 3.77; P = .04; Fig 3D) . There is a significant qualitative interaction between KRAS mutation and erlotinib-containing therapy (P = .01). Patients with KRAS wt tumors treated with erlotinib-containing therapy had significantly better OS compared with those treated with therapy that did not contain erlotinib (HR, 0.66; 95% CI, 0.45 to 0.97; P = .03; Fig 3E) , yet no difference in OS was seen among KRAS mut+ patients between these two treatment groups (HR, 0.26; 95% CI, 0.65 to 2.46; P = .50; Fig 3F) , and the influence of the interaction between KRAS mutation and erlotinibcontaining therapy on OS was not significant (P = .09). In arm 1, patients with KRAS mut+ tumors had a statistically significantly worse OS than those with KRAS wt tumors (median, 5.5 v 11.1 months; P = .02), but no significant differences were observed for KRAS mut+ compared with KRAS wt tumor-bearing patients in all other arms.
In tumors of 141 randomly assigned patients with adequate material for testing, we examined gene signatures described in the BATTLE study, including a sorafenib sensitivity signature generated from NSCLC cell lines and patient tumor biopsies 22 that was not predictive of outcome in this set of patients, as well as an EMT gene signature 23 that was associated with resistance in EGFR wt patients who received erlotinib. Patient tumors were scored to classify them as mesenchymal (EMT score . 0; n = 68) or epithelial (EMT score , 0; n = 73). There was no significant association between 8-week DCR and EMT score (Wilcoxon rank sum test P = .72; Data Supplement). EMT gene signature 23 analysis (Fig 4A) revealed that PFS was not different in epithelial versus mesenchymal tumors (Fig 4B) , whereas analysis by arm revealed improved PFS for patients with mesenchymal tumors treated with the MEK inhibitor (arm 3; P = .04; Data Supplement). A statistically significantly improved OS was seen in patients with mesenchymal tumors (log-rank test P = .02; Fig 4C) . The most pronounced effect was found for patients treated with sorafenib and among KRAS mut+ tumors (log-rank test P = .01; Data Supplement). Among rare responders, genomic profiling revealed an exon 19 deletion EGFR mutation on the erlotinib arm not detected at study entry (excluded from DCR analysis; Table 2 ), a KRAS G12C mutation, an ARAF mutation (R124H; predicted to be associated with sensitivity to MEK inhibition; first responder), an FBXW7 mutation (R479Q), and a short variant of unknown significance in the NOTCH1 gene both predicted to potentially contribute to sensitivity to AKT inhibition 24 (second responder) on arm 3 (MK-2206 and AZD6244).
Toxicity Toxicity, especially for the novel arms 2 and 3, was as expected on the basis of prior reports 16, 25 (Table 3) . Average treatment compliance was more than 95% in all arms. There was only one grade 5 event observed in the sorafenib arm: esophageal hemorrhage with a centrally located tumor invading the esophagus and death possibly related to treatment. The most common grade 3 to 4 toxicity in arm 2 was diarrhea (16.7%); in arm 3, maculopapular rash (9.3%), and arm 4 (sorafenib), fatigue (13.1%). Treatment discontinuation rate was 9%, 14%, 13%, and 15% and dose reductions and/or delays were necessary in 18%, 43%, 39%, and 41% in arms 1, 2, 3, and 4, respectively. Nineteen patients (6.9%) experienced biopsy-related pneumothorax, and only two patients (0.7%) required hospitalization for management.
DISCUSSION
The phase II randomized BATTLE-2 trial confirmed the feasibility of biopsy-mandated, biomarker-based, adaptively randomized clinical study design in patients with pretreated advanced NSCLC. The trial data demonstrated the following key points: there was no significant association between 8-week DCR and KRAS mutation status; patients with KRAS wt tumors treated with erlotinibcontaining therapy had better OS compared with those treated with therapy that did not contain erlotinib, whereas patients with KRAS mut+ tumors experienced longer PFS if treated with therapy that did not contain erlotinib and better 8-week DCR with MEK and AKT inhibitor therapy; and mesenchymal gene signature was associated with improved OS.
In all, 334 screened patients were needed to randomly assign 200 patients who reflected the heavily pretreated population with significant comorbid disease and declining PS, also underlying the response rate of 3.2% partially because of a lack of validated predictive markers. The 8-week DCR observed in BATTLE-2 (48%) is similar to that observed in BATTLE-1 6 (46%) despite the exclusion of erlotinib-naïve patients with EGFR-sensitizing mutations (15% of BATTLE-1 patients).
In BATTLE-2, we prespecified an extremely limited set of markers, and our intent was to use the first half of the study (200 patients) to conduct prospective testing of biomarkers and/or gene signatures. Predictive markers were to be used to guide patient assignments in the second half of the study. Although the design theoretically provided advantages because clear predictive markers did not exist for any of the treatment arms, activity was modest yielding no new predictive markers and not warranting further exploration.
However, several interesting observations were derived from the trial. The EMT signature, 23 was not predictive of DCR or PFS in the overall group, but patients with mesenchymal tumors treated with MK-2206 and AZD6244 had improved PFS and those with mesenchymal tumors had improved OS compared with patients www.jco.org Yes   CDS1  AP1M2  TMEM30B  MAPK13  MPP7  SCNN1A  EPCAM  BSPRY  TMEM45B  ST14  CLDN4  ELMO3  CRB3  KRTCAP3  INADL  EPB41L5  SH3YL1  ENPP5  STAP2  C1orf172  GRHL1  DSP  MAL2  CDH1  ESRP1  GRHL2  RAB25  F11R  GALNT3  SPINT2  ERBB3  PRSS8  CLDN7  TMC4  C1orf116  TMEM125  MUC1  TJP3  SHROOM3  RBPMS  TC2N  FXYD3  GPR56  EPN3  C3orf21  EPHA1  CDH3  EVPL  KLC3  TACSTD2  KRT19  S100A14  PRSS22  TNFRSF21  SERINC2  SSH3  ITGB6  MPZL2  GPR110  GALNT5  ANKRD22  PPARG  ZEB1  MMP2  LIX1L  VIM  AXL  FN1  TGFBI  HNMT  ANTXR2  NRP1 with epithelial tumors, an effect mostly driven by treatment with sorafenib. In a recent pan-cancer EMT analysis, there was a trend toward greater sensitivity of mesenchymal cell lines to sorafenib and to drugs that target PDGFR (overexpressed in mesenchymal tumors), consistent with the finding in this study. 26 Interestingly, this effect of EMT on OS (all arms, logrank test P = .02) and among sorafenib-treated patients (logrank test P = .01) was maintained among patients with KRAS mut+ tumors (Data Supplement). Sorafenib significantly reduces the epigenetic switching of critical EMT-associated genes by potentiating histone acetylation through regulation of expression of histone-modifying enzymes. 27 It can inhibit transforming growth factor b 1 -induced EMT and hepatocyte growth factor-mediated EMT in hepatocytes, 28 the latter effect being mediated by inhibition of MAPK signaling, possibly implicated in the improved PFS observed for patients with mesenchymal tumors treated with AZD6244.
29
A major focus of BATTLE-2 was exploration of the efficacy of combined AKT and MEK inhibition for KRAS mut+ patients. RAS signaling 30 is activated through growth factor receptors or somatic mutations seen in 25% of lung adenocarcinomas, frequently in the context of other co-mutations. RAS has been an elusive target for direct targeting.
31 Co-targeting of the Ras/Raf/MEK/ERK and PI3K/AKT parallel pathways on the basis of multiple points of cross-talk and negative feedback interactions 32 can blunt compensatory pathway activation leading to antitumor effects. Indeed, in a KRAS-mutant lung cancer mouse model, combined MEK and PI3K/mammalian target of rapamycin inhibition resulted in synergistic effects and tumor regression.
14 In this trial, we used two potent selective inhibitors, MK-2206, an AKT inhibitor, and AZD6244, a non-ATP competitive inhibitor of MEK, 33 a combination evaluated in a phase I study, 34 which was partially run in parallel with our study with encouraging results (23% response rate in KRAS mut+ NSCLC). There were only three partial responses: two had available genomic data and one harbored both a KRAS G12C and an ARAF mutation suggesting multiple inputs in the MAPK signaling pathway and possibly conferring increased sensitivity to MEK inhibition. The observed heterogeneity of response among patients with KRASmut+ cancers likely reflects the complex co-mutational landscape of KRAS mut+ tumors that defines biologically distinct subgroups with different therapeutic vulnerabilities. 35 Our experience mirrors that of several other trials evaluating combinations of PI3K/AKT and MEK inhibitors 25,36-38 that have www.jco.org demonstrated modest activity and poor tolerance to combinations related to on-target inhibition of the MAPK and PI3K pathways in normal tissues. Complex mutational background tumors encountered in heavily pretreated patients may be better addressed with novel immunotherapy agents 39, 40 or other combinations of targeted therapy with or without immunotherapy.
The BATTLE-2 study showed the utility of real-time biopsies for broad profiling of tumors that serve as a discovery vehicle for better target selection. We are currently pursuing alternative strategies in targeting KRAS mut+ tumors by incorporating knowledge derived from BATTLE-2.
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